Business
LEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
LEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \nRNS Number : 6082I Angle PLC 28 November 2018 \n\n\n\n\nFor immediate release\n\n\n 28 November 2018\n\n\n\n \nANGLE plc (\"the Company\")\n \nLEADING US HEMATOPATHOLOGIST APPOINTED AS SCIENTIFIC ADVISOR TO ANGLE\n \n \nANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce the appointment of Dr Joseph D Khoury as a Scientific Advisor to the Company's established Scientific Advisory Board. \n \nDr Khoury is a recognised expert in diagnostic pathology and has significant experience in the cytological and morphological analysis of cancer cells. His expertise is therefore highly relevant to ANGLE's continuing development of its ParsortixTM system as the liquid biopsy platform of choice for harvesting and analysing circulating tumour cells and other rare cells from blood as a means of diagnosing and monitoring disease. Dr Khoury is a tenured Professor of Pathology and Laboratory Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas and is the Executive Director of the MD Anderson Cancer Network for the Division of Pathology and Laboratory Medicine and the Director of the MD Anderson Institutional Immunohistochemistry Laboratory. \n \nDr Khoury is a leader in translational research focused on hematolymphoid neoplasia (a class of tumours that affect the blood, bone marrow, and organs of the immune system). He has authored over 150 publications and has trained numerous clinical and research fellows. He is an active member of the College of American Pathologists and has lectured extensively at various institutions and conferences globally.\n \n \nANGLE Founder and Chief Executive, Andrew Newland, commented: \n\"Our Parsortix system has been shown to enable the efficient harvesting of circulating cancer cells and other rare cells in patient blood. Dr Khoury's expertise in interpreting these cells and their relevance to a patient's condition, and potentially their prognosis and treatment, is expected to open up new possibilities for the use of Parsortix system. We are delighted that we will be able to benefit from his extensive expertise in this area.\"\n \nDr Joseph D Khoury, Executive Director, MD Anderson Cancer Network, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer ...